Metabolic effects of parenteral nutrition enriched with n-3 polyunsaturated fatty acids in critically ill patients

BACKGROUND & AIMS: n-3 fatty acids are expected to downregulate the inflammatory responses, and hence may decrease insulin resistance. On the other hand, n-3 fatty acid supplementation has been reported to increase glycemia in type 2 diabetes. We therefore assessed the effect of n-3 fatty acids delivered with parenteral nutrition on glucose metabolism in surgical intensive care patients. METHODS: Twenty-four surgical intensive care patients were randomized to receive parenteral nutrition providing 1.25 times their fasting energy expenditure, with 0.25 g of either an n-3 fatty acid enriched-or a soy bean-lipid emulsion. Energy metabolism, glucose production, gluconeogenesis and hepatic de novo lipogenesis were evaluated after 4 days. RESULTS: Total energy expenditure was significantly lower in patients receiving n-3 fatty acids (0.015+/-0.001 vs. 0.019+/-0.001 kcal/kg/min with soy bean lipids (P<0.05)). Glucose oxidation, lipid oxidation, glucose production, gluconeogenesis, hepatic de novo lipogenesis, plasma glucose, insulin and glucagon concentrations did not differ (all P>0.05) in the 2 groups. CONCLUSIONS: n-3 fatty acids were well tolerated in this group of severely ill patients. They decreased total energy expenditure without adverse metabolic effects.

Drug monographs on drugs which are frequently analysed in the context of Therapeutic Drug Monitoring = Arzneimittel-Monographien für Medikamente, die regelmässig im Rahmen des Therapeutic Drug Monitorings analysiert werden

In addition to the monographs which were published last year by the working group "Drug Monitoring" of the Swiss Society of Clinical Chemistry (SSCC) [1], new monographs have been written. The aim of these monographs is to give an overview of the most important information necessary for ordering a drug analysis or interpreting the results. Therefore, the targeted readers comprise laboratory health professionals and all receivers of laboratory reports. There is information provided on the indication for therapeutic drug monitoring, protein binding, metabolic pathways and enzymes involved, elimination half-life and elimination routes, and on therapeutic or toxic concentrations. Preanalytical considerations are of particular importance for therapeutic drug monitoring. Therefore, information is provided regarding a reasonable timing for the determination of drug concentrations as well as steady-state concentrations after changing the dose. Furthermore, the stability of the drug and its metabolite(s) after blood sampling is described. For readers with a specific interest in drug analysis, references to important publications are given. The number of monographs will be continuously enlarged. The updated files are presented on the homepage of the SSCC (www.sscc.ch).

Drug and Alcohol Knowledge and Use Amongst Primary School Children (PDF 246 KB)

Mar-04

Drug Problems - Can Substitute Prescribing Services Help You? Leaflet

Drug Problems - Can Substitute Prescribing Services Help You? Leaflet

Survey of Injecting Drug Users - 2002/2003 (PDF 152 KB)

Summary of the findings for 2002/03 from the five collaborating centres in NI

Survey of Injecting Drug Users - 2002 (PDF 165 KB)

Summary of the findings for 2002 from the five collaborating centres in NI

Drug and Alcohol Use Among Young People in NI (PDF 424 KB)

A Secondary Analysis of Drug and Alcohol Use Surveys - Final Report

Review of Drug Co-Ordination Teams - Final Report

Report by Deloitte & Touche October 2002

Drug Strategy for Northern Ireland (PDF 669 KB)

This document sets out the new Strategy for addressing drug misuse problems in Northern Ireland. With a vision for all who work towards addressing this problem, four main aims are identified along with a set of outcomes. The Strategy has a minimum lifespan of five years with a first major review after three years. Since its publication the NIO is no longer responsible for the drug strategy - this work has been taken over by the Department of Health, Social Services and Public Safety.